Connection

JAY BAKUL SHAH to Humans

This is a "connection" page, showing publications JAY BAKUL SHAH has written about Humans.
Connection Strength

0.126
  1. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecol Oncol. 2018 01; 148(1):181-188.
    View in: PubMed
    Score: 0.012
  2. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51.
    View in: PubMed
    Score: 0.009
  3. Strategies for optimizing bacillus Calmette-Gu?rin. Urol Clin North Am. 2013 May; 40(2):211-8.
    View in: PubMed
    Score: 0.008
  4. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res. 2011 May 01; 17(9):2608-12.
    View in: PubMed
    Score: 0.007
  5. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special? Cancer. 2011 Mar 01; 117(5):882-3.
    View in: PubMed
    Score: 0.007
  6. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther. 2010 Jun; 10(6):837-42.
    View in: PubMed
    Score: 0.007
  7. Clinical trials: nationally representative data in urology. Nat Rev Urol. 2009 Jul; 6(7):354-5.
    View in: PubMed
    Score: 0.007
  8. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol. 2008 Jan; 179(1):136-40.
    View in: PubMed
    Score: 0.006
  9. Water under the bridge: 5-year outcomes after percutaneous ablation of obstructing parapelvic renal cysts. J Endourol. 2007 Oct; 21(10):1167-70.
    View in: PubMed
    Score: 0.006
  10. New treatments for superficial bladder cancer. Curr Oncol Rep. 2006 May; 8(3):201-5.
    View in: PubMed
    Score: 0.005
  11. PSA updated: still relevant in the new millennium? Eur Urol. 2005 Apr; 47(4):427-32.
    View in: PubMed
    Score: 0.005
  12. Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol. 2004 Sep; 14(5):287-93.
    View in: PubMed
    Score: 0.005
  13. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy. Clin Cancer Res. 2023 05 15; 29(10):1969-1983.
    View in: PubMed
    Score: 0.004
  14. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.002
  15. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.002
  16. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.002
  17. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9.
    View in: PubMed
    Score: 0.002
  18. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol. 2013 Oct; 190(4):1404-9.
    View in: PubMed
    Score: 0.002
  19. Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther. 2013 Feb; 12(2):121-30.
    View in: PubMed
    Score: 0.002
  20. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ. 2013 Mar; 20(3):382-95.
    View in: PubMed
    Score: 0.002
  21. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):36-44.
    View in: PubMed
    Score: 0.002
  22. Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. 2013 Mar; 111(3):419-26.
    View in: PubMed
    Score: 0.002
  23. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
    View in: PubMed
    Score: 0.002
  24. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206.
    View in: PubMed
    Score: 0.002
  25. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int. 2011 Sep; 108(6 Pt 2):993-8.
    View in: PubMed
    Score: 0.002
  26. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther. 2010 Nov 01; 10(9):885-92.
    View in: PubMed
    Score: 0.002
  27. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 01; 116(19):4513-9.
    View in: PubMed
    Score: 0.002
  28. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44.
    View in: PubMed
    Score: 0.002
  29. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol. 2009 Nov-Dec; 27(6):585-91.
    View in: PubMed
    Score: 0.002
  30. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology. 2007 Oct; 70(4):706-10.
    View in: PubMed
    Score: 0.001
  31. Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J Urol. 2006 May; 175(5):1663-7; discussion 1667.
    View in: PubMed
    Score: 0.001
  32. Does year of radical prostatectomy independently predict outcome in prostate cancer? Urology. 2006 Feb; 67(2):368-72.
    View in: PubMed
    Score: 0.001
  33. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005 Sep; 174(3):827-34.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.